â– LECTURE OVERVIEW: Acute stroke represents a neurological emergency. Timely differentiation between ischemic and hemorrhagic profiles is critical to determine the therapeutic pathway.
â– CLINICAL DYNAMICS:
1. Ischemic Stroke (85% of cases):
- Origin: Caused by thrombotic or embolic occlusion of a cerebral artery, most commonly the Middle Cerebral Artery (MCA).
- Cascade: Focal tissue ischemia triggers an ischemic cascade, depleting ATP, causing cellular depolarization, toxic glutamate release, and ultimate necrotic cell death.
2. Hemorrhagic Stroke (15% of cases):
- Origin: Caused by the rupture of a blood vessel in the brain parenchyma (intracerebral hemorrhage, often from long-standing hypertension eroding Charcot-Bouchard aneurysms) or into the subarachnoid space (subarachnoid hemorrhage, often from a ruptured saccular berry aneurysm).
â– HISTOMEDICAL INTEGRATIVE MICROSPECTRA:
Ultrastructural analysis of target tissue reveals altered organelle density, high-yield ribosomal tagging, changes in basement membrane integrity, and specialized junction breakdown associated with functional deterioration.
â– PHARMACODYNAMIC TARGET ENGAGEMENT:
Receptor binding dynamics dictate the overall speed, duration, and magnitude of physiological responses to therapeutic agents.
[HY-BOARD-1371]
🌟 Dynamic Clinical Key:
A non-contrast head CT scan is the absolute first-line screening diagnostic of choice. Because acute ischemia is initially invisible on CT, the main purpose is to rule out hemorrhagic stroke before administering fibrinolytic agents like recombinant tPA, which would be fatal if given during active intracranial hemorrhage. Look for pathognomonic electron microscopy structures (e.g., zebra bodies, Birbeck granules) for confirmation of metabolic storage diseases. Watch closely for ligand-receptor saturation effects and subsequent tolerance or resistance.